Cargando…

Clinical and molecular characteristics of Chinese non‐small cell lung cancer patients with ERBB2 transmembrane domain mutations

Transmembrane domain (TMD) mutations of ERBB2 have previously been reported in lung cancer patients in addition to well‐studied kinase domain (KD) mutations, which may stabilize ERBB2 heterodimerization with other EGFR family members and favor a kinase active conformation. However, the frequency and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Yun, Qiu, Jinrong, Yu, Ruoying, Cao, Ran, Chen, Xiaoxi, Ou, Qiuxiang, Wu, Xue, Shao, Yang W., Nagasaka, Misako, Zhang, Jiexia, Ou, Sai‐Hong Ignatius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400783/ https://www.ncbi.nlm.nih.gov/pubmed/32478891 http://dx.doi.org/10.1002/1878-0261.12733

Ejemplares similares

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability
por: Wang, Hui, et al.
Publicado: (2022)

Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population
por: Lai, Xiaojing, et al.
Publicado: (2022)

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
por: Nagasaka, Misako, et al.
Publicado: (2022)

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
por: Brazel, Danielle, et al.
Publicado: (2023)

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

In Response to Dr. Steven Sorscher
por: Zhang, Shannon S., et al.
Publicado: (2022)

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature
por: Zhang, Shannon S., et al.
Publicado: (2022)

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
por: Anwar, Kaleem, et al.
Publicado: (2022)

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review
por: Zhu, Viola W., et al.
Publicado: (2020)

Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2021)

Absence of Activating Mutations in the Transmembrane Domain of the c‐erbB‐2 Proto‐oncogene in Human Lung Cancer
por: Sachse, Richard, et al.
Publicado: (1992)

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
por: Xia, Bing, et al.
Publicado: (2020)

Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study
por: Shi, Lei, et al.
Publicado: (2020)

Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases
por: Wang, Zhen, et al.
Publicado: (2022)

The Roles of Transmembrane Domain Helix-III during Rhodopsin Photoactivation
por: Ou, Wen-bin, et al.
Publicado: (2011)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Comprehensive genomic profiling of colorectal cancer patients reveals differences in mutational landscapes among clinical and pathological subgroups
por: Li, Peng, et al.
Publicado: (2022)

HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma
por: Jia, Ziqi, et al.
Publicado: (2021)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu, Viola W, et al.
Publicado: (2020)

Pan‐cancer molecular analysis of EGFR large fragment deletion in the Asian population
por: Pu, Jun, et al.
Publicado: (2023)

Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR
por: Wagner, Anja, et al.
Publicado: (2022)

Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes
por: Zhao, Weixin, et al.
Publicado: (2023)

Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review
por: Abuhelwa, Ziad, et al.
Publicado: (2022)

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
por: Kancha, Rama Krishna, et al.
Publicado: (2011)

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
por: Lopez, Michael, et al.
Publicado: (2023)

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
por: Ou, Sai-Hong Ignatius
Publicado: (2011)

Clinical and genomic analysis of baseline and acquired MET fusions with an intact kinase domain in lung cancer patients
por: Jin, Bo, et al.
Publicado: (2023)

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
por: Bekaii-Saab, Tanios, et al.
Publicado: (2006)

ERBB family fusions are recurrent and actionable oncogenic targets across cancer types
por: Schubert, Laura, et al.
Publicado: (2023)

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
por: Wang, Jinguang, et al.
Publicado: (2018)

Syndecan Transmembrane Domain Specifically Regulates Downstream Signaling Events of the Transmembrane Receptor Cytoplasmic Domain
por: Hwang, Jisun, et al.
Publicado: (2021)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
por: Zhang, Shannon S., et al.
Publicado: (2022)

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
por: Zhang, Shannon S, et al.
Publicado: (2022)

Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors
por: Yang, Zhen, et al.
Publicado: (2022)

Incorporating significant amino acid pairs to identify O-linked glycosylation sites on transmembrane proteins and non-transmembrane proteins
por: Chen, Shu-An, et al.
Publicado: (2010)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
por: Brazel, Danielle, et al.
Publicado: (2023)

Occult HBV infection in Chinese blood donors: role of N-glycosylation mutations and amino acid substitutions in S protein transmembrane domains
por: Zhang, Lu, et al.
Publicado: (2019)

Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas
por: Yamamoto, Hiromasa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sm6qb2a6f10s3ojpnftnri176s